Skip to content
ATRA·Nasdaq·US

Atara Biotherapeutics

Atara Biotherapeutics develops T-cell immunotherapies using its allogeneic Epstein-Barr virus T-cell platform for patients with cancer and autoimmune disease, positioning itself as a leader in this segment of the biotechnology industry. Its lead product, tab-cel (Ebvallo), is approved in the EEA, UK and Switzerland and is commercialized through a partnership with Pierre Fabre Medicament.

Source: SEC 10-K Mar 16, 2026

Thematic Position

ATRA

Relationship Groups

Competitors8

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

16 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

FDA approval requirementregulatory rejection
FDA second Complete Response Letter cites deficiencies in ALLELE trial design
SEC 10-QAug 12, 2026

The full regulatory passage is part of the Pro plan.

37 more · Regulatory and geopolitical insights are part of the Pro plan.